Novel therapeutic approach for Alzheimer's disease by removing amyloid β protein from the brain with an extracorporeal removal system

Kazunori Kawaguchi, Nobuya Kitaguchi, Shigeru Nakai, Kazutaka Murakami, Kunihiko Asakura, Tatsuro Mutoh, Yoshiro Fujita, Satoshi Sugiyama

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The accumulation of amyloid beta (Aβ) protein in the brain reflects the cognitive impairment noted in Alzheimer's disease. Recent studies have shown that brain Aβ disappeared and cognitive improvement occurred as a result of passive or active Aβ immunization. Peripheral administration of nonimmunization substances, such as GM1 ganglioside, also reduced brain Aβ. Therefore, we hypothesized that the rapid removal of Aβ from the blood by an extracorporeal system may act as a peripheral Aβ sink from the brain. In the present study, we investigated the Aβ removal activity of medical materials as a first step toward the design of an Aβ removal system. First, the removal activities of six materials were studied for Aβ 1-40 and Aβ 1-42 by batch analysis in albumin solution or in human plasma for 1-16 h. Two of the six materials reduced the Aβ concentrations by 90-99% within 1 h. Next, the two effective materials, hexadecyl-alkylated cellulose particles (HDC) and charcoal, were analyzed in a continuous single-pass system with minicolumns. Both materials showed around 81-90% removal activity for more than 2 h, which corresponded to over 4 l of plasma treatment in humans. In a human extracorporeal system, HDC also removed both Aβ 1-40 and Aβ 1-42 from whole blood circulation. In conclusion, biomedical materials were found that could remove Aβ 1-40 and Aβ 1-42 effectively in an extracorporeal system. It is now conceivable that further studies can be undertaken to reduce Aβ concentrations in the brain to improve cognitive function.

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalJournal of Artificial Organs
Volume13
Issue number1
DOIs
Publication statusPublished - 01-04-2010

Fingerprint

Amyloidogenic Proteins
Brain
Alzheimer Disease
Cellulose
G(M1) Ganglioside
Therapeutics
Serum Amyloid A Protein
Blood Circulation
Charcoal
Amyloid beta-Peptides
Plasma (human)
Immunization
Cognition
Hemodynamics
Albumins
Amyloid
Vaccination
Blood
Proteins
Plasmas

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering
  • Cardiology and Cardiovascular Medicine

Cite this

Kawaguchi, Kazunori ; Kitaguchi, Nobuya ; Nakai, Shigeru ; Murakami, Kazutaka ; Asakura, Kunihiko ; Mutoh, Tatsuro ; Fujita, Yoshiro ; Sugiyama, Satoshi. / Novel therapeutic approach for Alzheimer's disease by removing amyloid β protein from the brain with an extracorporeal removal system. In: Journal of Artificial Organs. 2010 ; Vol. 13, No. 1. pp. 31-37.
@article{1616a47d023249d68f7ad81a9448d6e3,
title = "Novel therapeutic approach for Alzheimer's disease by removing amyloid β protein from the brain with an extracorporeal removal system",
abstract = "The accumulation of amyloid beta (Aβ) protein in the brain reflects the cognitive impairment noted in Alzheimer's disease. Recent studies have shown that brain Aβ disappeared and cognitive improvement occurred as a result of passive or active Aβ immunization. Peripheral administration of nonimmunization substances, such as GM1 ganglioside, also reduced brain Aβ. Therefore, we hypothesized that the rapid removal of Aβ from the blood by an extracorporeal system may act as a peripheral Aβ sink from the brain. In the present study, we investigated the Aβ removal activity of medical materials as a first step toward the design of an Aβ removal system. First, the removal activities of six materials were studied for Aβ 1-40 and Aβ 1-42 by batch analysis in albumin solution or in human plasma for 1-16 h. Two of the six materials reduced the Aβ concentrations by 90-99{\%} within 1 h. Next, the two effective materials, hexadecyl-alkylated cellulose particles (HDC) and charcoal, were analyzed in a continuous single-pass system with minicolumns. Both materials showed around 81-90{\%} removal activity for more than 2 h, which corresponded to over 4 l of plasma treatment in humans. In a human extracorporeal system, HDC also removed both Aβ 1-40 and Aβ 1-42 from whole blood circulation. In conclusion, biomedical materials were found that could remove Aβ 1-40 and Aβ 1-42 effectively in an extracorporeal system. It is now conceivable that further studies can be undertaken to reduce Aβ concentrations in the brain to improve cognitive function.",
author = "Kazunori Kawaguchi and Nobuya Kitaguchi and Shigeru Nakai and Kazutaka Murakami and Kunihiko Asakura and Tatsuro Mutoh and Yoshiro Fujita and Satoshi Sugiyama",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s10047-010-0482-3",
language = "English",
volume = "13",
pages = "31--37",
journal = "Journal of Artificial Organs",
issn = "1434-7229",
publisher = "Springer Japan",
number = "1",

}

Novel therapeutic approach for Alzheimer's disease by removing amyloid β protein from the brain with an extracorporeal removal system. / Kawaguchi, Kazunori; Kitaguchi, Nobuya; Nakai, Shigeru; Murakami, Kazutaka; Asakura, Kunihiko; Mutoh, Tatsuro; Fujita, Yoshiro; Sugiyama, Satoshi.

In: Journal of Artificial Organs, Vol. 13, No. 1, 01.04.2010, p. 31-37.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel therapeutic approach for Alzheimer's disease by removing amyloid β protein from the brain with an extracorporeal removal system

AU - Kawaguchi, Kazunori

AU - Kitaguchi, Nobuya

AU - Nakai, Shigeru

AU - Murakami, Kazutaka

AU - Asakura, Kunihiko

AU - Mutoh, Tatsuro

AU - Fujita, Yoshiro

AU - Sugiyama, Satoshi

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The accumulation of amyloid beta (Aβ) protein in the brain reflects the cognitive impairment noted in Alzheimer's disease. Recent studies have shown that brain Aβ disappeared and cognitive improvement occurred as a result of passive or active Aβ immunization. Peripheral administration of nonimmunization substances, such as GM1 ganglioside, also reduced brain Aβ. Therefore, we hypothesized that the rapid removal of Aβ from the blood by an extracorporeal system may act as a peripheral Aβ sink from the brain. In the present study, we investigated the Aβ removal activity of medical materials as a first step toward the design of an Aβ removal system. First, the removal activities of six materials were studied for Aβ 1-40 and Aβ 1-42 by batch analysis in albumin solution or in human plasma for 1-16 h. Two of the six materials reduced the Aβ concentrations by 90-99% within 1 h. Next, the two effective materials, hexadecyl-alkylated cellulose particles (HDC) and charcoal, were analyzed in a continuous single-pass system with minicolumns. Both materials showed around 81-90% removal activity for more than 2 h, which corresponded to over 4 l of plasma treatment in humans. In a human extracorporeal system, HDC also removed both Aβ 1-40 and Aβ 1-42 from whole blood circulation. In conclusion, biomedical materials were found that could remove Aβ 1-40 and Aβ 1-42 effectively in an extracorporeal system. It is now conceivable that further studies can be undertaken to reduce Aβ concentrations in the brain to improve cognitive function.

AB - The accumulation of amyloid beta (Aβ) protein in the brain reflects the cognitive impairment noted in Alzheimer's disease. Recent studies have shown that brain Aβ disappeared and cognitive improvement occurred as a result of passive or active Aβ immunization. Peripheral administration of nonimmunization substances, such as GM1 ganglioside, also reduced brain Aβ. Therefore, we hypothesized that the rapid removal of Aβ from the blood by an extracorporeal system may act as a peripheral Aβ sink from the brain. In the present study, we investigated the Aβ removal activity of medical materials as a first step toward the design of an Aβ removal system. First, the removal activities of six materials were studied for Aβ 1-40 and Aβ 1-42 by batch analysis in albumin solution or in human plasma for 1-16 h. Two of the six materials reduced the Aβ concentrations by 90-99% within 1 h. Next, the two effective materials, hexadecyl-alkylated cellulose particles (HDC) and charcoal, were analyzed in a continuous single-pass system with minicolumns. Both materials showed around 81-90% removal activity for more than 2 h, which corresponded to over 4 l of plasma treatment in humans. In a human extracorporeal system, HDC also removed both Aβ 1-40 and Aβ 1-42 from whole blood circulation. In conclusion, biomedical materials were found that could remove Aβ 1-40 and Aβ 1-42 effectively in an extracorporeal system. It is now conceivable that further studies can be undertaken to reduce Aβ concentrations in the brain to improve cognitive function.

UR - http://www.scopus.com/inward/record.url?scp=77951254201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951254201&partnerID=8YFLogxK

U2 - 10.1007/s10047-010-0482-3

DO - 10.1007/s10047-010-0482-3

M3 - Article

VL - 13

SP - 31

EP - 37

JO - Journal of Artificial Organs

JF - Journal of Artificial Organs

SN - 1434-7229

IS - 1

ER -